A Clinical Study to Determine the Safety and Efficacy of Bio-Ray Knee Guard in Panelists with Varicose Vein and Knee Pain.
NCT ID: NCT06440889
Last Updated: 2025-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
63 participants
INTERVENTIONAL
2024-05-31
2024-10-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Sample size for this proof-of-science study is kept 32 panelists aged 35 to 70 years with self-declared knee pain and varicose veins will be enrolled and 32 healthy panelists will be enrolled.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genicular Artery Embolization for the Treatment of Knee Osteoarthritis
NCT03491397
Bayer OA Knee Pain Pilot
NCT05349682
Treatment of Knee Osteoarthritis (KOA) by Injection of Autologous Adipose-derived Vascular Matrix Components (SVF) Into Joint Cavity
NCT06109220
High Frequency Intensive Autologous PRP Injection and Genicular Nerve Blocks in Treating Knee Osteoarthritis
NCT04088045
Intraarticular Leukocyte-rich and Leukocyte-poor PRP for Osteoarthritis of the Knee
NCT05737173
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Panelists shall be instructed to visit the facility for the following scheduled visits:
Visit 01 (Day 01): Screening, enrolment, evaluations at baseline, test product and \*subject diary distribution, followed by evaluations after 1 hour (+10 minutes).
Visit 02 (Day 03 +1 day): Evaluations at Day 03 (+1 day).
Visit 03 (07 ±2 days): 1-week evaluations at Day 07 (±2 days).
Visit 04 (28±2 days): Subject diary review, followed by end of study evaluations.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Varicose Vein Group
Ebene Bio-Ray Knee Guard Wear the test product in the daytime for about 1-2 hours. Then, proceed to gradually lengthen the duration of wear to 4-6 and 6-8 hours.
Bio-Ray Knee Guard
Wear the metal guard (test product) for 1-2 hours during the first week, and then for 6-8 hours thereafter. (minimum for 4 hours)
Healthy Group
Ebene Bio-Ray Knee Guard Wear the test product in the daytime for about 1-2 hours. Then, proceed to gradually lengthen the duration of wear to 4-6 and 6-8 hours.
Bio-Ray Knee Guard
Wear the metal guard (test product) for 1-2 hours during the first week, and then for 6-8 hours thereafter. (minimum for 4 hours)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bio-Ray Knee Guard
Wear the metal guard (test product) for 1-2 hours during the first week, and then for 6-8 hours thereafter. (minimum for 4 hours)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Non-pregnant and non-lactating adult females having a self-reported negative urine pregnancy test.
3. Panelist of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, vasectomy or abstinence).
4. 32 panelists with clinical diagnosis of varicose veins in any of the leg with C2 class as per CEAP classification (Appendix II), with self-declared knee pain.
5. 32 healthy panelists will be enrolled.
6. Documented written informed consent from the panelists.
7. Panelists having willingness and ability to adhere to study directions, and agreeing not to use any other or wear any other similar product at the same designated site for this study and returning for all specified visits for follow-up.
8. Panelists are currently not enrolled in an active investigational study or have participated in similar investigational study within 30 days prior to enrolment.
Exclusion Criteria
2. Any recent surgery which may hinder in the study specific assessments and overall outcome.
3. Panelists with class C3 to C6 of CEAP classification.
4. Panelists who are currently on medication therapy for varicose veins, deep vein thrombosis or chronic venous insufficiency.
5. Panelists taking or have taken medication(s) which, in the Investigator's judgment, make them ineligible or places them at undue risk.
6. Panelists are currently enrolled in an active investigational study or have participated in an investigational study within 30 days prior to enrolment.
7. Females who are pregnant or breastfeeding or planning to become pregnant during the study period.
8. Panelists who are not willing to adhere to the study protocol.
35 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Winnox Cosmeceutics Sdn. Bhd
INDUSTRY
NovoBliss Research Pvt Ltd
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Nayan Patel
Sub-Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. Nayan K Patel K Patel
Role: PRINCIPAL_INVESTIGATOR
NovoBliss Research Pvt Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NovoBliss Research Pvt.Ltd
Ahmedabad, Gujarat, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NB240023-WU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.